Skip to main content
. 2014 Nov 15;141(22):4254–4266. doi: 10.1242/dev.115436

Fig. 6.

Fig. 6.

p21 (Waf1/Cip1) induced by Sox9 inhibits Sox2 expression through direct binding to SRR2 enhancer. (A) Growth profiles of SOX9-inducible ESCs cultured in Dox+ (control) or Dox− conditions (three independent experiments; data are mean±s.e.m.; *P<0.05 and **P<0.01 versus Dox+). (B) Cell cycle profiles of SOX9-inducible ESCs cultured for 2 days (D2) or 5 days (D5) in Dox+ (control) or Dox− conditions (the independent experiments). (C) qPCR analyses showing the changes in expression of p21, p27, p53 and Rb in SOX9-inducible ESCs cultured in Dox+ (control) or Dox− conditions. (D) Examples of western blots detecting POU5F1, NANOG, SOX2, P21 and β-actin (control) in SOX9-inducible ESCs cultured in Dox+ (control) or Dox− conditions. (E) A summary of three independent western blots, presented as a percent fraction of β-actin (data are mean±s.e.m.; *P<0.05 versus Dox+). (F) Regulatory regions in the murine Sox2 locus. (G) ChIP assays examining the binding of SOX9 to the UTR and the SRR2 enhancer region of Sox2, and to the Nanog promoter region in SOX9-inducible ESCs cultured after 1 day (D1), 3 days (D3) or 5 days (D5). Three independent experiments; data are mean±s.e.m.; *P<0.05 and **P<0.01 versus Dox+. Red, Dox−; blue, Dox+.